Free Trial

Icon (ICLR) Stock Forecast & Price Target

Icon logo
$193.89 +0.93 (+0.48%)
Closing price 10/3/2025 04:00 PM Eastern
Extended Trading
$193.86 -0.03 (-0.02%)
As of 10/3/2025 04:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Icon - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
9
Buy
11

Based on 20 Wall Street analysts who have issued ratings for Icon in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 20 analysts, 9 have given a hold rating, 9 have given a buy rating, and 2 have given a strong buy rating for ICLR.

Consensus Price Target

$217.33
12.09% Upside
According to the 20 analysts' twelve-month price targets for Icon, the average price target is $217.33. The highest price target for ICLR is $311.00, while the lowest price target for ICLR is $150.00. The average price target represents a forecasted upside of 12.09% from the current price of $193.89.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ICLR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Icon and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ICLR Analyst Ratings Over Time

TypeCurrent Forecast
10/6/24 to 10/6/25
1 Month Ago
9/6/24 to 9/6/25
3 Months Ago
7/8/24 to 7/8/25
1 Year Ago
10/7/23 to 10/6/24
Strong Buy
2 Strong Buy rating(s)
3 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
11 Buy rating(s)
Hold
9 Hold rating(s)
6 Hold rating(s)
7 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$217.33$219.64$213.08$351.60
Forecasted Upside12.09% Upside25.60% Upside40.57% Upside19.78% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyBuy

ICLR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ICLR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Icon Stock vs. The Competition

TypeIconMedical CompaniesS&P 500
Consensus Rating Score
2.65
2.33
2.51
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside12.09% Upside1,395.17% Upside10.49% Upside
News Sentiment Rating
Positive News

See Recent ICLR News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
10/2/2025Barclays
3 of 5 stars
Luke Sergott
Luke Sergott
Not Rated
Boost TargetEqual Weight$180.00 ➝ $190.00-1.20%
9/27/2025Weiss Ratings
0 of 5 stars
 Reiterated RatingHold (C)
9/12/2025Cowen
1 of 5 stars
 Reiterated RatingHold
9/9/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$220.00 ➝ $175.00-1.58%
9/3/2025Rothschild Redb
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldStrong-Buy
9/3/2025Rothschild & Co Redburn
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeNeutralBuy$184.00 ➝ $236.00+32.70%
9/2/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$222.00 ➝ $224.00+27.11%
8/21/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuyNeutral$225.00 ➝ $200.00+10.96%
7/25/2025Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$173.00 ➝ $225.00+22.29%
7/25/2025Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$187.00 ➝ $234.00+26.14%
7/25/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$170.00 ➝ $240.00+29.32%
7/25/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$170.00 ➝ $240.00+28.37%
7/24/2025Baird R W
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 UpgradeHoldStrong-Buy
5/2/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower TargetNeutral$180.00 ➝ $160.00+9.30%
4/29/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeOverweightNeutral$265.00 ➝ $150.00+3.45%
4/14/2025TD Cowen
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuyHold$254.00 ➝ $157.00+9.00%
1/15/2025Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$263.00 ➝ $263.00+29.67%
1/14/2025William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
11/19/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOutperform$270.00 ➝ $255.00+34.38%
10/14/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$311.00+5.43%
9/18/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:11 AM ET.


Should I Buy Icon Stock? ICLR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Saturday, October 4, 2025. Please send any questions or comments about these Icon pros and cons to contact@marketbeat.com.

Icon
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in ICON Public Limited:

  • The company reported earnings per share (EPS) of $3.26 for the latest quarter, exceeding expectations, which indicates strong financial performance and effective management.
  • ICON Public Limited has set its fiscal year 2025 guidance at an EPS range of 13.000-14.000, suggesting confidence in future profitability and growth.
  • Institutional investors own a significant majority (95.61%) of the company's stock, which often reflects confidence in the company's long-term prospects.
  • The current stock price is around $169, which may present a buying opportunity for investors looking for growth in the medical research sector.
  • Despite a slight year-over-year revenue decline, the company still generated $2.02 billion in revenue, surpassing analyst estimates, indicating resilience in its business model.

Icon
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in ICON Public Limited for these reasons:

  • The company's revenue decreased by 4.8% compared to the same quarter last year, which may raise concerns about its growth trajectory.
  • ICON Public Limited's EPS of $3.26 is lower than the $3.75 reported in the same quarter last year, indicating a decline in profitability.
  • The price-to-earnings (P/E) ratio of 18.27 may suggest that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • The company has a beta of 1.20, indicating that its stock is more volatile than the market, which could pose risks for conservative investors.
  • Recent trading volumes have been significantly lower than average, which may indicate reduced investor interest or liquidity concerns.

ICLR Forecast - Frequently Asked Questions

According to the research reports of 20 Wall Street equities research analysts, the average twelve-month stock price forecast for Icon is $217.33, with a high forecast of $311.00 and a low forecast of $150.00.

20 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Icon in the last twelve months. There are currently 9 hold ratings, 9 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ICLR shares.

According to analysts, Icon's stock has a predicted upside of 12.09% based on their 12-month stock forecasts.

Over the previous 90 days, Icon's stock had 4 upgrades and 1 downgrade by analysts.

Analysts like Icon more than other "medical" companies. The consensus rating for Icon is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ICLR compares to other companies.


This page (NASDAQ:ICLR) was last updated on 10/6/2025 by MarketBeat.com Staff
From Our Partners